Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02842723 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 25, 2016
Last Update Posted : August 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Craniopharyngioma | Radiation: Protontherapy | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 33 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Phase II Study on the Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy |
| Actual Study Start Date : | March 2010 |
| Actual Primary Completion Date : | November 13, 2018 |
| Estimated Study Completion Date : | December 2020 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Protontherapy |
Radiation: Protontherapy
59,5 Gy (1,7 Gy daily, 5 fractions per week). |
- local control rate at 3 years of a minimally aggressive surgical resection, followed by fractionated high precision radiotherapy [ Time Frame: at 3 years ]
- visual pathway tolerance according to NCI-CTC v3.0 scale [ Time Frame: through study completion, up to 9 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 3 Years to 16 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically documented craniopharyngioma
- Age range between 3 and 16 years
- Landsky performance status > 60
- Incomplete surgical resection or simple biopsy
- Solid and/or cystic aspect on imaging
- Irradiation performed at the time of presentation or of local progression
- Signed informed consent by parents or by legal representative (with copy to each participating center)
Exclusion Criteria:
- Previous history of radiotherapy (including stereotactic) administered to the head and neck region
- Severe vasculopathy
- Participation to a concurrent study
- Contra-indication to general anesthesia in children below 5 years
- Patient non-compliant to a minimum 30 mn immobilisation
- Patient deprived of freedom or under guardianship
- Patient not expected to be followed in a long run
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02842723
| France | |
| Institut Curie | |
| Paris, France, 75005 | |
| Groupe Hospitalier Necker Enfants Malades | |
| Paris, France, 75015 | |
| Gustave Roussy | |
| Villejuif, France, 94800 | |
| Responsible Party: | Institut Curie |
| ClinicalTrials.gov Identifier: | NCT02842723 |
| Other Study ID Numbers: |
IC 2008-01 |
| First Posted: | July 25, 2016 Key Record Dates |
| Last Update Posted: | August 7, 2020 |
| Last Verified: | August 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
craniopharyngioma protontherapy |
|
Craniopharyngioma Adamantinoma Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Nerve Tissue Bone Neoplasms Neoplasms by Site Bone Diseases Musculoskeletal Diseases |

